2. UroToday Home
  3. Categories

Bladder Cancer

Ethnicity and race as modifiers of the association between patient sex and stage at diagnosis of bladder cancer.

With over 80,000 projected new diagnoses in 2024, bladder cancer remains a significant public health concern. Given the absence of routine screening protocols, identifying high-risk populations becomes crucial for early detection and intervention.

Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective, Single-centre Trial.

Bladder cancer (BC) represents a significant health care challenge and is frequently detected during evaluations for haematuria in emergency departments (EDs). Our aim was to evaluate the clinical performance and economic implications of the Xpert BC Detection (BCD) test for patients presenting to the ED with haematuria to address the pressing need for more efficient and accurate diagnostic tools in this setting.

Distinct Gene Expression Patterns Identify Patients who Relapse after Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study - Beyond the Abstract

In recent years, several clinical trials have been evaluating the use of systemic immune checkpoint inhibitor (ICI) treatment for patients with locally (advanced) urothelial cancer. For patients who are platinum eligible, several trials combine multiple ICI drugs or ICI with chemotherapy, including BLASST-1, NIAGARA, and KEYNOTE-866.

A New AI Model for Grading Non-Muscle Invasive Bladder Cancer - Expert Commentary

Accurate grading and staging of non-muscle invasive bladder cancer (NMIBC) is critical for prognosis and treatment selection. The advent of digital pathology and artificial intelligence (AI) has yielded promising results in reducing subjectivity and enhancing accuracy. Recently, Shalata et al. developed a convolutional neural network (CNN) model, termed ShuffleNet, and tested its performance in pathologic grading NMIBC.

Impact of race-based calculations of eGFR on the management of muscle invasive bladder cancer.

The estimated glomerular filtration rate (eGFR) has historically been calculated with a race-coefficient multiplier (RCM); however, the RCM has been broadly criticized as inaccurate and a potential contributor to exacerbating disparities.

AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses.

Non-muscle-invasive Bladder Cancer (NMIBC) is notorious for its high recurrence rate of 70-80%, imposing a significant human burden and making it one of the costliest cancers to manage. Current prediction tools for NMIBC recurrence rely on scoring systems that often overestimate risk and lack accuracy.

Precise grading of non-muscle invasive bladder cancer with multi-scale pyramidal CNN.

The grading of non-muscle invasive bladder cancer (NMIBC) continues to face challenges due to subjective interpretations, which affect the assessment of its severity. To address this challenge, we are developing an innovative artificial intelligence (AI) system aimed at objectively grading NMIBC.

Is pT0 a Reliable End Point for Biomarker Discovery for Preoperative Chemotherapy Response in Patients with Bladder Cancer?

Purpose: Traditional biomarker investigation schemas for chemotherapy response prediction in patients with bladder cancer relying on the pT0 status at radical surgery are confounded by the therapeutic effect of transurethral resection of bladder tumor (TURBT). Studying cN+ patients and assessing pN0 status presents a unique opportunity for overcoming this bias.

A multicenter study of perioperative and functional outcomes of open vs. robot assisted uretero-enteric reimplantation after radical cystectomy.

Open ureteroenteric reimplantation (OUER) of ureteroenteric strictures (UESs) is related to important morbidity. Robot-assisted ureteroenteric reimplantation (RUER) has been proposed to provide similar outcomes with lower morbidity.

En bloc resection of large bladder tumor: is it feasible and reasonable?

Transurethral resection of bladder tumor (TURBT) remains the basis of bladder tumor diagnosis and an effective means of treating nonmuscle invasive bladder cancer (NMIBC). There are several limitations to this procedure: TURBT may cause free floating of malignant cells in the bladder and as a result re-implantation and early recurrence.

Page 1 of 1100